Skip to content

HEMOTECH BELUX: what changed

BE 0474.412.845NACE 46.460, Wholesale of pharmaceutical and medical goodsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€23,980
2024 · €118,944-€94,964
Equity
€859,416
2024 · €835,437+€23,980
Cash
€0
2024 · €170-€170
Balance sheet total
€5.0m
2024 · €4.3m+€637,397

Largest movements

2024 to 2025
Assets
  • Receivables within one year +€495,001

    up €495,001 (+22.9%), from €2.2m to €2.7m

    of which Trade receivables: +€1.2m

  • Stocks and contracts +€274,450

    up €274,450 (+20.2%), from €1.4m to €1.6m

    of which Stocks: +€292,450

  • Intangible fixed assets -€111,559

    down €111,559 (-18.3%), from €609,889 to €498,330

Equity and liabilities
  • Other debts +€858,065

    up €858,065 (+83.7%), from €1.0m to €1.9m

  • Trade debts -€209,122

    down €209,122 (-15.4%), from €1.4m to €1.1m

  • Advances received -€150,121

    down €150,121 (-62.8%), from €239,092 to €88,972

  • Tax, wage and social debts +€101,114

    up €101,114 (+56.9%), from €177,807 to €278,922

    of which Taxes: +€120,131

Income statement
  • Staff costs +€89,105

    up €89,105 (+8.8%), from €1.0m to €1.1m

  • Taxes +€81,705

    up €81,705 (+3,227%), from €2,532 to €84,237

  • Depreciation +€79,213

    up €79,213 (+75.5%), from €104,939 to €184,152

  • Gross operating margin +€48,079

    up €48,079 (+3.4%), from €1.4m to €1.5m

  • Other operating charges -€19,698

    down €19,698 (-53.1%), from €37,103 to €17,405

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €118,944
Gross operating margin +€48,079
Staff costs -€89,105
Depreciation -€79,213
Write-downs -€4,300
Other operating charges +€19,698
Other operating items +€72,241
Financial income +€6,114
Financial charges +€13,226
Taxes -€81,705
Result 2025 €23,980
raises the resultlowers the resultnot broken down further in the accounts

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€46,425
Investment -€46,595
Financing €0
Cash 2024 €170
Net result for the year +€23,980
Depreciation +€184,152
Stocks and contracts -€274,450
Receivables within one year -€495,001
Deferred charges and accrued income -€5,673
Trade debts -€209,122
Tax, wage and social debts +€101,114
Advances received -€150,121
Other debts +€858,065
Accrued charges and deferred income +€13,481
Investment in fixed assets (net) -€46,595
Cash 2025 €0
brings cash intakes cash out
Every line side by side 48 lines
Line Code 2024 2025 Change %
Total assets 20/58 €4,320,400 €4,957,797 +€637,397 +14.8%
Fixed assets 21/28 €730,912 €593,355 -€137,557 -18.8%
Intangible fixed assets 21 €609,889 €498,330 -€111,559 -18.3%
Tangible fixed assets 22/27 €120,993 €94,995 -€25,998 -21.5%
Plant, machinery and equipment 23 €43,038 €30,284 -€12,754 -29.6%
Furniture and vehicles 24 €43,948 €35,206 -€8,741 -19.9%
Other tangible fixed assets 26 €34,008 €29,505 -€4,503 -13.2%
Financial fixed assets 28 €30 €30 = 0.0%
Current assets 29/58 €3,589,488 €4,364,442 +€774,954 +21.6%
Stocks and contracts in progress 3 €1,356,233 €1,630,683 +€274,450 +20.2%
Stocks 30/36 €1,338,233 €1,630,683 +€292,450 +21.9%
Contracts in progress 37 €18,000 €0 -€18,000 -100%
Amounts receivable within one year 40/41 €2,162,911 €2,657,913 +€495,001 +22.9%
Trade receivables 40 €1,480,012 €2,648,183 +€1.2m +78.9%
Other amounts receivable 41 €682,899 €9,729 -€673,170 -98.6%
Cash at bank and in hand 54/58 €170 €0 -€170 -100%
Deferred charges and accrued income 490/1 €70,173 €75,846 +€5,673 +8.1%
Total equity and liabilities 10/49 €4,320,400 €4,957,797 +€637,397 +14.8%
Equity 10/15 €835,437 €859,416 +€23,980 +2.9%
Contributions 10/11 €900,894 €900,894 = 0.0%
Profit (loss) carried forward 14 -€65,458 -€41,478 +€23,980 +36.6%
Amounts payable 17/49 €3,484,963 €4,098,381 +€613,417 +17.6%
Amounts payable after more than one year 17 €630,000 €630,000 = 0.0%
Financial debts 170/4 €630,000 €630,000 = 0.0%
Amounts payable within one year 42/48 €2,800,060 €3,399,997 +€599,937 +21.4%
Trade debts 44 €1,358,150 €1,149,028 -€209,122 -15.4%
Suppliers 440/4 €1,358,150 €1,149,028 -€209,122 -15.4%
Advances received on contracts in progress 46 €239,092 €88,972 -€150,121 -62.8%
Taxes, remuneration and social security 45 €177,807 €278,922 +€101,114 +56.9%
Taxes 450/3 €27,593 €147,723 +€120,131 +435%
Remuneration and social security 454/9 €150,215 €131,199 -€19,016 -12.7%
Other amounts payable 47/48 €1,025,010 €1,883,075 +€858,065 +83.7%
Accrued charges and deferred income 492/3 €54,903 €68,384 +€13,481 +24.6%
Remuneration, social security and pensions 62 €1,017,971 €1,107,076 +€89,105 +8.8%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €104,939 €184,152 +€79,213 +75.5%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) 631/4 -€14,360 -€10,061 +€4,300 +29.9%
Other operating charges 640/8 €37,103 €17,405 -€19,698 -53.1%
Non-recurring operating charges 66A €73,970 €1,729 -€72,241 -97.7%
Gross operating margin 9900 €1,420,533 €1,468,612 +€48,079 +3.4%
Operating profit (loss) 9901 €200,910 €168,310 -€32,600 -16.2%
Financial income 75/76B €16,193 €22,308 +€6,114 +37.8%
Recurring financial income 75 €16,193 €22,308 +€6,114 +37.8%
Financial charges 65/66B €95,627 €82,401 -€13,226 -13.8%
Recurring financial charges 65 €95,627 €82,401 -€13,226 -13.8%
Profit (loss) for the period before taxes 9903 €121,476 €108,216 -€13,260 -10.9%
Income taxes 67/77 €2,532 €84,237 +€81,705 +3,227%
Profit (loss) for the period 9904 €118,944 €23,980 -€94,964 -79.8%
Profit (loss) for the period to be appropriated 9905 €118,944 €23,980 -€94,964 -79.8%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€221,283 to €237,578

Midpoint €228,072 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Adjusted equity €361,086
Capitalised earnings €81,479 to €114,070
Indication €221,283 to €237,578

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€859,416
Intangible fixed assets (21)
-€498,330
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€361,086

Capitalised earnings

net result for the year (9904)
2025
€23,980
excluding non-recurring income and charges
€25,709
2024
€118,944
excluding non-recurring income and charges
€192,914
2023
-€184,402
2022
-€285,130
excluding non-recurring income and charges
-€297,130
2021
-€34,880
excluding non-recurring income and charges
-€30,367
Average result, excluding non-recurring income and charges
€11,407
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€81,479 / €95,058 / €114,070

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.